Navigation Links
WuXi PharmaTech and Open Monoclonal Technology Announce OmniRat(TM) Antibody Collaboration

SHANGHAI and PALO ALTO, Calif., Sept. 4, 2012 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, and Open Monoclonal Technology, Inc. (OMT), an innovator in novel transgenic animals for development of human therapeutic antibodies, today announced that they have entered into an agreement to use OMT's OmniRat™ to develop therapeutic antibody candidates for commercialization by WuXi's global customers.

This transaction advances WuXi's goal of working with skilled partners to enhance the company's platform of technologies and capabilities to serve its customers better.

The OmniRat™ technology generates fully human antibodies with great specificity, affinity and manufacturability. It eliminates time-consuming humanization of traditional mouse-derived antibodies and the need for optimization of lead candidates using phage display technology.

"OMT's OmniRat™ technology allows WuXi to expand its service offerings in discovery of fully human antibodies," said Edward Hu, Chief Operating Officer and Chief Financial Officer of WuXi PharmaTech. "Providing discovery, development and manufacturing services for novel therapeutic antibodies represents an important new global business initiative for WuXi. We are investing heavily in building our capabilities and capacity in biologics services, which we expect to be a key driver of revenue growth for our company in the coming years."

Dr. Roland Buelow, founder and CEO of OMT, continued, "The collaboration with WuXi further advances OMT's efforts to deploy its human antibody platform globally. Under the collaboration, OMT can leverage WuXi's expertise and capacity to create novel therapeutic candidates for its biopharmaceutical customers and apply OMT's technology to an ever-broadening base of drug candidates."

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners shorten the cycle and lower the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

About Open Monoclonal Technology, Inc. - naturally optimized human antibodies™

Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for development of human therapeutic antibodies. OMT has developed OmniRat™, the first fully human monoclonal antibody platform based on transgenic rats. OmniRat is based on an improved understanding of B cell development and a novel approach to inactivation of endogenous antibody expression. These transgenic animals make antibodies as efficiently as wild type animals. OmniRat is a new and proprietary technology with unrestricted development options for fully human monoclonal antibodies across all targets and indications worldwide.

For more information

Please visit, or contact:

Ronald Aldridge
Director of Investor Relations
WuXi PharmaTech (Cayman) Inc.
Phone:  +1-201-585-2048

Brian Lundstrom
Chief Business Officer
Open Monoclonal Technology, Inc.
Phone:  +1-510-220-5599



SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
2. Industry Leading Pharmaceutical News Website Refocused and Relaunched
3. WuXi PharmaTech Announces First-Quarter 2012 Results
4. Pharmatech Oncology Receives Phase 2 SBIR Funding for Just-In-Time Enrollment Model
5. WuXi PharmaTech Announces Second-Quarter 2012 Results
6. WuXi PharmaTech Receives GLP Certificate from SFDA for Suzhou Toxicology Facility
7. WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics
8. VLST Corporation Announces In-licensing Agreement with Pfizer for Anti-CD40 Monoclonal Antibody
9. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
10. Fujitsu to Showcase Radiation-Hardened RFID Using FRAM Technology at Interphex 2012 in New York City, Booth #2430
11. SolutionStart Corp. Announces John Karagiannis as Vice President of Technology
Post Your Comments:
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their ... Award, an essay contest in which patients and their families pay tribute to a ... the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & ... (TGIG), has initiated cultivation and processing operations at its production facility, and opened ... , Puradigm is the manufacturer of a complete system of proactive air and ...
Breaking Medicine News(10 mins):